2017年不可手术胰腺癌的治疗选择
胰腺腺癌分为转移性胰腺腺癌(MPA)和局部晚期胰腺癌(LAPC),1996至2011年间患者结局无改善,但近5年出现新治疗选择。新一线标准方案如FOLFIRINOX和吉西他滨联合白蛋白结合型紫杉醇改善了总生存,二线治疗已验证;其他一线治疗失败,但研究活跃。MPA新方案在LAPC开放队列或II期试验中显示有希望结果,近期试验未能证明经典外照射放疗的附加价值。本文综述LAPC和MPA当前标准治疗、最新挑战与战略问题及未来展望。
要点
- 新一线标准方案FOLFIRINOX和吉西他滨联合白蛋白结合型紫杉醇改善总生存。
- 二线治疗已被测试和验证。
- 近期试验未能证明经典外照射放疗在LAPC中的附加价值。
核心结论
- 近5年出现新治疗选择,新一线标准方案改善总生存,二线治疗已验证,但其他一线治疗失败,研究仍活跃。
- MPA新方案在LAPC开放队列或II期试验中显示有希望结果,近期试验未能证明经典外照射放疗的附加价值。
研究设计与样本
- 综述,回顾LAPC和MPA当前标准治疗、最新挑战与战略问题及未来展望。
主要发现
- 1996至2011年间患者结局无改善。
- 新一线标准方案如FOLFIRINOX和吉西他滨联合白蛋白结合型紫杉醇改善了总生存。
- 二线治疗已被测试和验证。
- 其他一线治疗失败。
- MPA新方案在LAPC开放队列或II期试验中显示有希望结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pancreatic adenocarcinoma is a frequent and severe disease, either diagnosed as metastatic pancreatic adenocarcinoma (MPA) or as locally advanced pancreatic carcinoma (LAPC). Though no improvement in patients outcome have been made between 1996 and 2011, since 5 years new treatment options have become available to treat our patients. New standard first line regimens, such as FOLFIRINOX and gemcitabine combined with nab-paclitaxel, have improved overall survivals and second line treatments have been tested and validated. Other first-line treatments have failed, but research remains active and trials are ongoing with promising new anti-cancer agents. These new effective regimens used for MPA have yielded promising results in LAPC patients in open cohorts or phase II trials and a recent trial have failed to demonstrate the added value of classical external radiotherapy in this setting. Here, we review current standards of care in LAPC and MPA, consider the latest challenges and strategic questions, and examine what we may hope for in the future.
引用
- Taieb J, Pointet AL, Van Laethem JL, et al. What treatment in 2017 for inoperable pancreatic cancers? Ann Oncol. 2017. PMID: 28459988. doi:10.1093/annonc/mdx174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。